Chinese Pre-Profit Cancer Drug Developer Tot Biopharm Files For HK IPO

Login to View

Tot Biopharm, a private equity-backed Chinese biopharmaceutical company, has filed for an initial public offering (IPO) in Hong Kong on Monday under the rules that allow pre-profit companies to float shares on the stock exchange.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in